Metabolic Optimization · Reviewed by Ian K. Tseng, MD

What Is Tesamorelin? A Longer-Acting GHRH Analog

Tesamorelin sits in the same mechanistic family as sermorelin — both are growth-hormone-releasing hormone analogs — but differs in two ways worth understanding: a structural modification that extends its stability, and an FDA-approved indication that most compounds in this space do not have.

Published August 4, 2026 · Medical review by Ian K. Tseng, MD, Medical Director

The structural difference from sermorelin

Sermorelin is the first 29 amino acids of natural GHRH — the minimal fragment retaining activity. Tesamorelin is based on the full GHRH sequence with a trans-3-hexenoyl group attached, a modification that increases resistance to enzymatic degradation.

Practically, that means a longer duration of action. Both compounds work through the same receptor and the same upstream mechanism: prompt the pituitary, preserve the feedback loop, retain the pulsatile release pattern. The difference is stability, and therefore dosing profile.

If the GHRH mechanism itself is unfamiliar, our sermorelin explainer walks through how prompting release differs from injecting growth hormone directly.

The FDA-approved indication, stated precisely

Tesamorelin is FDA-approved for the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. That is the approved indication, and stating it precisely matters.

An FDA approval is specific to an indication and a population — it is not a general endorsement of a molecule for any purpose. The approval means this compound was studied in that population, for that outcome, and met the regulatory standard. Use outside that indication is off-label, and the approval does not establish benefit for general fat loss or body composition in other populations. Compounded tesamorelin is a separate matter: it has not been through FDA review, and its current eligibility for 503A compounding is unsettled.

What the visceral fat research examined

The clinical research supporting the approval measured visceral adipose tissue — the metabolically active fat surrounding the abdominal organs, distinct from subcutaneous fat under the skin. Visceral adiposity is of clinical interest because it associates with metabolic and cardiovascular risk in ways that subcutaneous fat does not to the same degree.

Measured outcomes in those trials were imaging-based assessments of visceral adipose tissue alongside metabolic markers. As with all therapy in this category, individual results vary, and research findings in one studied population do not automatically transfer to another.

Visceral vs. subcutaneous fat

• 1Skin — The outer surface, at the very top of the section.
• 2Subcutaneous fat — The pale yellow layer sitting directly beneath the skin, outside the muscle wall — what you can pinch. Less metabolically active, and not the compartment these trials measured.
• 3Abdominal muscle wall — The red band dividing the two fat compartments. Everything above it is subcutaneous; everything below is visceral.
• 4Visceral fat — The deeper fat packed inside the muscle wall, around and between the organs. Metabolically active, and the compartment associated with metabolic and cardiovascular risk.
• 5Abdominal organs — The intestinal loops visceral fat surrounds, which is why it is assessed by imaging rather than by a tape measure.

Monitoring the growth hormone axis

Because tesamorelin acts on the GH axis, the monitoring parallels sermorelin. Baseline IGF-1 is required — it is the practical readout of GH activity, since growth hormone itself is released in pulses and resists single-draw interpretation. IGF-1 is retested during therapy.

Growth hormone reduces insulin sensitivity, so fasting glucose and insulin are reviewed at baseline and monitored. A physician also evaluates thyroid function and general metabolic markers. Active malignancy is a contraindication, given the growth-promoting nature of the GH/IGF-1 axis. Our bloodwork explainer covers the full panel.

Related reading

• What Is Sermorelin
• What Is Semaglutide
• What Is MOTS-c
• How the Soothe IV peptide therapy program works

Frequently asked questions

This article is educational and is not medical advice. Statements have not been evaluated by the FDA. Peptide therapy is a physician-supervised medical service; specific protocols are determined individually after a Good Faith Examination and bloodwork, and not all applicants qualify. Some compounded medications used in physician-prescribed protocols are not FDA-approved. Data from clinical trials on FDA-approved medications should not be used to make assessments related to compounded medications. Soothe IV's peptide program is available via telehealth in 47 states and Washington, D.C. (every state except Alabama, Alaska and Mississippi); prescriptions are issued by clinicians licensed in your state.